SIRION Biotech started its business in 2005 in Munich, with the goal of sparking a new generation of viral vector technologies for cell and gene therapy, and vaccine development. This meant building novel, all-encompassing viral vector platforms for adeno-associated virus (AAV), lentivirus (LV), and adenovirus (AV).
SIRION Biotech is now the leading European developer and manufacturer of viral vectors for research and preclinical applications. To date we have completed over 2000 projects of all sizes, working closely with over 600 clients from academia and industry, 400 of whom have ordered multiple times. We also offer LentiBOOST®, a highly effective lentiviral transduction enhancer for therapeutic cell types like CAR-T cells and CD34+ hematopoietic stem cells. LentiBOOST® is currently included in more than 20 Phase III and I/II clinical trials.
We are committed to enabling our partners to develop the most successful vectors for their applications. We guide our customers through the entire Cell & Gene Therapy value chain – from capsid evolution and clinical vector design to reduce vector dose and improve therapeutic success, to supporting them with our process and development experience and manufacture of high-quality clinically compliant viral vectors for late preclinical applications.
- Area de Negocio
- Terapia génica
- Terapia celular
- Terapia Tisular
- Enfermedades genéticas
- Cultivos celulares
- Centros de investigación
- Biología celular y molecular
- Vectores virales
- Tipo de Empresa
- Biotecnología sanitaria
- Organizaciones públicas y privadas - Centros de investigación - Medical Facilities
Am Klopferspitz 19
Martinsried, Martinsried 82152, DE
T: +49 89 700 961 99 9
6, rue des Bateliers
CLICHY, CLICHY 92110, FR
T: +33 7 87 14 19 06
Spain - Main contact : Monserrat Vázquez-Rojas
Spain , Spain Spain , ES
T: +33 6 33 71 03 49
Dr. Christian Thirion
Chief Executive Officer, Founder
Christian O. Thirion, Ph.D serves as Chief Executive Officer, Chief Technology Officer, and founder of SIRION Biotech GmbH since 2005. Prior founding SIRION Christian was a postdoctoral fellow at the Department of Gene Therapy at Universitätsklinikum Ulm and led a team for neuromuscular disorders research at the Universitätsklinikum der Ludwig-Maximilians-Universität München. Christian holds a Ph.D in Biochemistry and holds a diploma in Chemistry, both from Ludwig-Maximilians-Universität München.
Dr. Michael Salomon
Senior Vice President, Development
Michael joined SIRION Biotech in September 2007. Prior, he acted as leader of a research group at the Botanical Institution of Ludwig-Maximilians-University Munich (LMU) and as Head of Research and Development at Vertis Biotechnology AG in Freising, Weihenstephan. His special expertise over the years has been with viral vector technologies. He received his Ph.D. in biology at the LMU in Munich, Germany in 1991.
Dr. Monserrat Vazquez Rojas
Key Account Manager
Monserrat joined SIRION Biotech in January 2021. She holds a PhD in Oncology from the University of Nice Côte d’Azur, France. Her scientific research was focused on the molecular biology of metastasis in Breast Cancer. She has joined SIRION in order to support the gene and cell therapy field, in Southern and Western Europe territories and especially in Spain.
SIRION Biotech are experts in the development and manufacture of AAV, Lentivirus, and Adenovirus. We offer clients services in the following areas:
Discovery and Preclinical Services
•High level of project customization and flexible design via expert support
•Customized scales & QC packages for R&D and preclinical studies
•State of the art USP / DSP
•Non-GMP platform manufacturing for in vivo PoC studies
Cell & Gene Therapy Clinical Support
•Development of clinically compliant viral vector design
•Optimizing the safety and quality of the vector
•Optimizing the efficacy of “therapeutic payload” cassette
•Process development and optimization
•Vector productivity evaluation and non-GMP manufacturing of late preclinical batches
•Under development: GMP-compliant process transfer and validated assay transfer to CDMO
•CDMO network establishment
•LentiBOOST® transduction enhancer with proven clinical success
•BAC technology & Ad19a/64 for R&D and clinical applications
SIRION Biotech offers expert support for all stages of your viral vector project, whether you are working with AAV, Lentivirus, or Adenovirus. Each project has an experienced and dedicated manager to work with you to develop the ideal vector for your needs and customize the scale and QC procedures to meet your requirements.
We have well established platform manufacturing processes, and are constantly working on improvement of all upstream and downstream process stages. Our high quality standards ensure repeat customers and client recommendations.
If you are moving towards cell or gene therapy applications, our Clinical Support team can help with vector design for optimum safety and efficacy, and our GMP Alliance team will help transfer your project and assays to the CMO of your choice.
Our laboratories are located in Munich, Germany, and ideally situated to serve the Spanish viral vector market.
Our clients are researchers and product developers working with AAV, Lentivirus, or Adenovirus vectors for gene transfer. They can be found in both academic and research institutes, and commercial companies pursuing drug discovery or developing cell and gene therapies.
Clients may have very little knowledge of viral vectors and rely on our highly qualified development teams or may be experts in viral vector technologies looking for a reliable, high quality, manufacturing partner.
Our clients share a desire to develop the ideal vector and have it manufactured to the highest quality standards.